Pipotiazine, sold as Piportil and Piportil L4 by Sanofi, is a piperidine phenothiazine antipsychotic developed in France in the 1960s. It is most commonly used as a long-acting depot — pipotiazine palmitate, an oily intramuscular injection given once every 4 weeks. The drug was never approved by the US FDA but has been used for decades in Canada, the United Kingdom (until production was discontinued there in the 2010s), continental Europe, parts of Africa, and Latin America. It remains in active use in some healthcare systems and is included here for the many patients and families who encounter it outside the US.
Pipotiazine palmitate is a once-monthly depot phenothiazine antipsychotic used internationally for maintenance treatment of schizophrenia, with an effect profile similar to other depot phenothiazines and never marketed in the United States.
How it works
Pipotiazine blocks dopamine D2 receptors. Receptor binding includes some affinity for histamine H1 and muscarinic receptors, with intermediate sedation and anticholinergic burden — between high-potency depot fluphenazine and lower-potency oral chlorpromazine.
Pipotiazine palmitate
Pipotiazine palmitate is the parent drug esterified with palmitic acid and dissolved in sesame oil. After deep intramuscular injection (usually gluteal), the ester is slowly hydrolysed to release pipotiazine into the bloodstream over weeks. Typical maintenance doses described in international labelling are 50 to 100 mg every 4 weeks, with a starting dose often around 25 mg and adjustments based on response and tolerability. Some patients are stable on lower doses, particularly older adults.
Indications and use
Pipotiazine is used as maintenance treatment for schizophrenia in adults — particularly when adherence to daily oral medication is a problem. Like other depot antipsychotics, it is generally not used for acute first-episode treatment because dose adjustments are slow. Most prescribers stabilise the patient on an oral antipsychotic first, then transition to depot.
Side effects
Movement effects
Acute dystonia, parkinsonism, akathisia. Anticholinergic medications are sometimes co-prescribed. Tardive dyskinesia risk accumulates over years, as with other typical antipsychotics.
Sedation, anticholinergic, orthostatic
Generally moderate. Less prominent than chlorpromazine, more than fluphenazine.
Hyperprolactinemia
Substantial. Sexual dysfunction, menstrual changes, breast changes, bone density concerns over years.
Cardiovascular
QT prolongation possible. Orthostatic hypotension can occur.
Injection site reactions
Pain, redness, induration are common. Rotating sites and using deep gluteal injection technique helps.
Hepatic and haematologic
Rare cholestatic effects and blood dyscrasias have been reported as class effects of phenothiazines.
Severe muscle stiffness with high fever and confusion, sudden severe involuntary movements, fainting, or signs of an allergic reaction.
Boxed warnings (international labelling)
International labels generally include the standard antipsychotic warning about increased mortality in elderly patients with dementia-related psychosis. Cardiac and movement-disorder warnings are also included.
Drug interactions
Additive sedation with CNS depressants. Additive QT effects with other QT-prolonging drugs. Anticholinergic effects compound those of other anticholinergics. Always disclose all medications and supplements.
Where pipotiazine fits today
In settings where it remains available, pipotiazine is used:
- For maintenance of schizophrenia in patients with adherence challenges
- When fluphenazine or haloperidol depots have not been tolerated
- In healthcare systems where second-generation depots are not available or affordable
- In patients who have done well on it historically
In the UK, Sanofi discontinued production of Piportil Depot in 2015 because of manufacturing reasons rather than safety concerns; some patients had to be transitioned to alternatives, often other depot typicals or second-generation depots. In Canada and continental Europe, it has remained in use.
If you encounter pipotiazine in records
Patients who immigrate to the US after being on pipotiazine elsewhere will need to switch to an antipsychotic available in the US — most commonly an equivalent depot such as fluphenazine decanoate, haloperidol decanoate, or a second-generation depot. The transition should be done with a prescriber who is experienced with cross-titration of depot antipsychotics.
Practical questions for patients on pipotiazine
- What is my dose and injection interval?
- What movement side effects should I monitor for?
- What are the alternatives if pipotiazine is no longer available locally?
- What should I do if I miss an injection?
- Should I have an anticholinergic on hand?
The big picture
Pipotiazine is one of the medications that demonstrates how regional the antipsychotic market actually is. A drug that has been used for fifty years in some countries is unknown in others. For patients who have been stable on it, pipotiazine is a working option. For those moving to the US, the equivalent agents are fluphenazine decanoate or haloperidol decanoate among typicals, or paliperidone palmitate, aripiprazole monohydrate, or risperidone formulations among atypicals. The transition is best planned with a knowledgeable prescriber.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling, regulatory sources, and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.